A Violaceous Nodule in a Lung-transplant Patient

Posttransplantation lymphoproliferative disorder (PTLD) is a rare complication of solid organ or allogenic bone marrow transplantation. Cases localized to the skin are even rarer, with only around 100 cases recorded in the literature [2]. We present a case of 60 year-old-woman, a lung transplant rec...

Full description

Saved in:
Bibliographic Details
Published in:Dermatology online journal 2016-06, Vol.22 (6)
Main Authors: Milford, Emily, Winslow, Caroline, Danhof, Rebecca
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Female
Graft Rejection - prevention & control
Humans
Immunocompromised Host
Immunosuppressive Agents - adverse effects
Leg
Lung Transplantation
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - etiology
Lymphoma, Large B-Cell, Diffuse - immunology
Lymphoma, Large B-Cell, Diffuse - pathology
Middle Aged
Neoplasm Recurrence, Local - etiology
Neoplasm Recurrence, Local - immunology
Neoplasm Recurrence, Local - pathology
Pulmonary Disease, Chronic Obstructive - surgery
Rituximab - therapeutic use
Skin Neoplasms - drug therapy
Skin Neoplasms - etiology
Skin Neoplasms - immunology
Skin Neoplasms - pathology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Posttransplantation lymphoproliferative disorder (PTLD) is a rare complication of solid organ or allogenic bone marrow transplantation. Cases localized to the skin are even rarer, with only around 100 cases recorded in the literature [2]. We present a case of 60 year-old-woman, a lung transplant recipient, who presented with an asymptomatic violaceous nodule on her left medial calf. Histopathology was consistent with PTLD of the B-cell subtype, EBV negative. This case is unique in that it was of the B cell subtype of cutaneous PTLD, which has been less commonly observed than the T cell subtype. In addition, the case was EBV negative, which is rare in B cell cutaneous PTLD. The patient was treated with rituximab 600 mg IV weekly for four weeks and cytomegalovirus immune globulin (Cytogam) 100 mg/kg once, with resolution of the nodule.
ISSN:1087-2108
1087-2108
DOI:10.5070/D3226031328